摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-hydroxy-5-methoxy-benzenesulfonic acid | 79852-04-3

中文名称
——
中文别名
——
英文名称
2-hydroxy-5-methoxy-benzenesulfonic acid
英文别名
2-Hydroxy-5-methoxybenzene-1-sulfonic acid;2-hydroxy-5-methoxybenzenesulfonic acid
2-hydroxy-5-methoxy-benzenesulfonic acid化学式
CAS
79852-04-3
化学式
C7H8O5S
mdl
——
分子量
204.204
InChiKey
CDQTVTSDYVLCHM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.516±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    92.2
  • 氢给体数:
    2
  • 氢受体数:
    5

SDS

SDS:6b67406ee0e9194c8f06cd20cb955198
查看

反应信息

  • 作为反应物:
    描述:
    2-hydroxy-5-methoxy-benzenesulfonic acid硫酸 作用下, 生成 2-Hydroxy-5-methoxybenzene-1,4-disulfonic acid 、 2-Hydroxy-5-methoxybenzene-1,3-disulfonic acid
    参考文献:
    名称:
    Cerfontain, Hans; Koeberg-Telder, Ankie, Recueil des Travaux Chimiques des Pays-Bas, 1988, vol. 107, p. 583 - 591
    摘要:
    DOI:
  • 作为产物:
    描述:
    4-甲氧基苯酚三氧化硫重水 作用下, 以 硝基甲烷 为溶剂, 以8%的产率得到2-hydroxy-5-methoxy-benzenesulfonic acid
    参考文献:
    名称:
    Cerfontain, Hans; Coenjaarts, Norbert J.; Koeberg-Telder, Ankie, Recueil des Travaux Chimiques des Pays-Bas, 1989, vol. 108, # 1, p. 7 - 13
    摘要:
    DOI:
  • 作为试剂:
    参考文献:
    名称:
    [EN] METHOD FOR PRODUCING PHENOL AND ACETONE
    [FR] PROCÉDÉ DE PRODUCTION DE PHÉNOL ET D'ACÉTONE
    摘要:
    一种在高温下通过多阶段过程从异丙苯过氧化氢混合物中生产苯酚和丙酮的方法,所述混合物包括异丙苯,该方法包括以下步骤:a)将异丙苯过氧化氢混合物与浓度为0.1至1毫摩尔/升的2-羟基苯磺酸催化剂反应,形成包括苯酚、丙酮和双异丙基过氧化物的第二混合物,并在第二阶段分解第二混合物以产生包括苯酚和丙酮的第三混合物。
    公开号:
    WO2010045423A1
点击查看最新优质反应信息

文献信息

  • An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant
    申请人:INTERx RESEARCH CORPORATION
    公开号:EP0036534A1
    公开(公告)日:1981-09-30
    A drug form is provided for increasing the oral absorption of β-lactam antibiotics such as the penicillins, cephalosporins and related chemical species by the oral administration of said β-lactam antibiotics in a suitable pharmaceutically accepted excipient to which has been added a hydroxy aryl or hydroxy aralkyl acid or salt, amide or ester thereof. The hydroxyaryl or hydroxyaralkyl acid or salt, amide or ester thereof is present in the drug form in quantities sufficient to be effective in enhancing the rate of oral absorption of the β-lactam antibiotic.
    本发明提供了一种药物形式,通过将β-内酰胺类抗生素口服于适当的药学上可接受的赋形剂中,并在赋形剂中加入羟基芳基或羟基芳烷基酸或其盐、酰胺或酯,从而增加β-内酰胺类抗生素如青霉素类、头孢菌素类及相关化学物质的口服吸收。羟基芳基或羟基烷基酸或其盐、酰胺或酯在药物形式中的含量足以有效提高 β-内酰胺类抗生素的口服吸收率。
  • An orally administered drug form comprising a polar bioactive agent and an adjuvant
    申请人:INTERx RESEARCH CORPORATION
    公开号:EP0036145A1
    公开(公告)日:1981-09-23
    A drug form is provided for increasing the oral absorption of polar bioactive agents such as xanthines, polyhydroxylic substances, zwitterions, polypeptides and organic anions and related chemical species by the oral administration of said polar bioactive agents in a suitable pharmaceutically accepted excipientto which has been added a hydroxyaromatic, hydroxyaryl or hydroxy aralkyl acid or salt amide or ester thereof. The hydroxy aryl or hydroxy aralkyl acid or salt amide or ester thereof is present in the drug form in quantities suffi- cientto be effective in enhancing the rate of oral absorption of the polar bioactive agents.
    本发明提供了一种药物剂型,用于增加极性生物活性剂(如黄嘌呤、多羟基物质、 齐聚物、多肽和有机阴离子及相关化学物质)的口服吸收,方法是将所述极性生物活性 剂口服在一种适当的药学上可接受的赋形剂中,在赋形剂中添加羟基芳基、羟基芳基或 羟基烷基酸或其酰胺盐或酯。羟基芳基或羟基烷基酸或其酰胺盐或酯在药物形式中的存在量足以有效提高极性生物活性剂的口服吸收率。
  • Targeted enteral delivery system
    申请人:R.P. SCHERER CORPORATION
    公开号:EP0225189A2
    公开(公告)日:1987-06-10
    A capsule for oral administration of a pharmaceutically active ingredient contains a pharmaceutical composition comprising the active ingredient, for example, a peptide, an absorption promoter and usually, a carrier. The absorption promoter is capable of enhancing absorption of the active ingredient from the intestine into the bloodstream. The capsule is coated with a film forming composition, which film is sufficiently insoluble at a pH below 7 as to be capable of protecting the capsule and its contents from the digestive juices until the capsule reaches a region below the upper part of the intestine, whereupon the coating and capsule are capable of eroding or dissolving to release the active ingredient for absorption into the bloodstream.
    一种用于口服药物活性成分的胶囊含有一种药物组合物,其中包括活性成分(如肽)、吸收促进剂和载体。吸收促进剂能够促进活性成分从肠道进入血液的吸收。胶囊表面涂有一层成膜组合物,这层膜在 pH 值低于 7 时具有足够的不溶性,能够保护胶囊及其内容物不受消化液的影响,直到胶囊到达肠道上部以下的区域,此时涂层和胶囊能够被侵蚀或溶解,释放出活性成分供血液吸收。
  • Polymeric acetal resins containing free radical inhibitors and their use in lithographic printing
    申请人:Kodak Polychrome Graphics GmbH
    公开号:EP1350801A1
    公开(公告)日:2003-10-08
    Polymeric acetal resins useful in lithographic printing are disclosed. The polymeric acetal resin contains units (A), (B), (C), (D), and (E). Unit (A) is a vinyl alcohol unit. Unit; (B) is a polyvinyl acetal unit containing an R group, where R is hydrogen, an aliphatic group, an aromatic group, or an arylaliphatic group. Unit (C) is a vinyl carboxylate unit. Unit (D) is an acidic vinyl acetal unit and/or a residue of an acidic vinyl monomer. Unit (E) is a free radical polymerization-inhibiting vinyl acetal unit and/or a free radical polymerization-inhibiting vinyl alcohol ester unit. The resin comprises about 10 to about 60 mol% of unit (A), about 5 to about 60 mol% of unit (B), about 0.3 to about 30 mol% of unit (C), about 1 to about 40 mol% of unit (D), and about 0.01 to about 2 mol% of unit (E).
    本发明公开了用于平版印刷的聚合缩醛树脂。聚合缩醛树脂包含单元 (A)、(B)、(C)、(D) 和 (E)。单元(A)是乙烯醇单元。单元(B)是含有 R 基团的聚乙烯醇缩醛单元,其中 R 是氢、脂肪族基团、芳香族基团或芳基脂肪族基团。单元(C)是乙烯基羧酸酯单元。单元(D)是酸性乙烯基缩醛单元和/或酸性乙烯基单体的残余物。单元(E)是自由基聚合抑制乙缩醛单元和/或自由基聚合抑制乙烯醇酯单元。该树脂包括约 10 至约 60 摩尔%的单元(A)、约 5 至约 60 摩尔%的单元(B)、约 0.3 至约 30 摩尔%的单元(C)、约 1 至约 40 摩尔%的单元(D)和约 0.01 至约 2 摩尔%的单元(E)。
  • CERFONTAIN, HANS;COENJAARTS, NORBERT J.;KOEBERG-TELDER, ANKIE, REC. TRAV. CHIM. PAYS-BAS, 108,(1989) N, C. 7-13
    作者:CERFONTAIN, HANS、COENJAARTS, NORBERT J.、KOEBERG-TELDER, ANKIE
    DOI:——
    日期:——
查看更多